PATENT COOPERATION TREAT

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER		see Form PCT/ISA/220	
RLL-482WO	ACTION	as wel	as, where applicable, item 5 below.	
International application No.	International filing date (day/mon	th/year)	(Earliest) Priority Date (day/month/year)	
PCT/IB2005/000132	19/01/2005	5	19/01/2004	
Applicant	<u> </u>			
RANBAXY LABORATORIES LIMI	TED			
This International Search Report has bee according to Article 18. A copy is being tr			nority and is transmitted to the applicant	
This International Search Report consists	s of a total of <u>8</u> sh	neets.	•	
X It is also accompanied by	a copy of each prior art document	cited in this	report.	
	international search was carried ou less otherwise indicated under this		sis of the international application in the	
The international this Authority (Ru		s of a transl	ation of the international application furnished	to
b. With regard to any nucle	otide and/or amino acid sequenc	e disclosed	in the international application, see Box No. I.	
2. Certain claims were fou	and unsearchable (See Box II).			_
3. X Unity of invention is lac	king (see Box III).		. 1	BEST AVAILABLE
4. With regard to the title ,				7
the text is approved as su	ubmitted by the applicant.			8
	shed by this Authority to read as followed			\geq
AMORPHOUS MAGNESIUM SA	ALTS OF ROSUVASTATIN ~			≽
	•			8
				m
	•			2
				COPY
				~
5. With regard to the abstract,				
the text is approved as su	ibmitted by the applicant.			
			y as it appears in Box No. IV. The applicant the report, submit comments to this Authority.	
6. With regard to the drawings,				
a. the figure of the drawings to be p	published with the abstract is Figure	No		
as suggested by t	the applicant.			
as selected by thi	s Authority, because the applicant for	ailed to sug	gest a figure.	
	s Authority, because this figure bett	er characte	rizes the invention.	
b. X none of the figures is to be	e published with the abstract.			

Box No. IV Text of the abstract (Continuation of item 5 of the first sheet)

The invention provides the novel amorphous rosuvastatin magnesium and process for preparation thereof from crystalline rosuvastatin magnesium, rosuvastatin methyl ammonium salt and from rosuvastatin lactone.

Rosuvastatin magnesium is, chemically, (3R,5S,6E)-7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-6-heptenoic acid, magnesium salt (2:1) of Formula I.

FORMULA I

Rosuvastatin magnesium is an antihypercholesterolemic drug used in the treatment of atherosclerosis.

* **ernational Application No

CT/IB2005/000132

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07D239/42

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 CO7D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BEILSTEIN Data

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 01/60804 A (ASTRAZENECA AB; ASTRAZENECA UK LIMITED; SHIONOGI & CO., LTD; TAYLOR, N) 23 August 2001 (2001-08-23) cited in the application claim 15; example 10	1-19
X	claims 1,11,15; example 9	6,7
Y	US 6 589 959 B1 (TAYLOR NIGEL P) 8 July 2003 (2003-07-08) cited in the application column 2, lines 11-40	1-19
X	EP 0 521 471 A (SHIONOGI SEIYAKU KABUSHIKI KAISHA) 7 January 1993 (1993-01-07) cited in the application page 2, lines 12-45; claim 1; examples 1,7 page 2, line 53 - page 4, line 15	1-5, 17-19

X Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
 Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed 	 *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family
Date of the actual completion of the international search . 30 June 2005	Date of mailing of the international search report 1 8, 07, 05
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Schuemacher, A

5

***ernational Application No
. cT/IB2005/000132

Category °	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Calegory 5	Guanon of document, with indication, where appropriate, of the relevant passages	nelevani io ciaim No.
Α .	WO 03/016317 A1 (TEVA PHARMACEUTICAL INDUSTRIES LTD., ISRAEL; TEVA PHARMACEUTICALS USA,) 27 February 2003 (2003-02-27) page 2, lines 15-32; claim 24; examples 7,8	16
Р,А	WO 2004/014872 A1 (ASTRAZENECA UK LIMITED, UK) 19 February 2004 (2004-02-19) page 2, lines 18-30; claims 1,15	16
Ρ,Χ	WO 2004/108691 A1 (ASTRAZENECA UK LIMITED, UK) 16 December 2004 (2004-12-16) page 15, lines 8-15; claim 1	1-19
E	WO 2005/021511 A1 (HETERO DRUGS LIMITED, INDIA) 10 March 2005 (2005-03-10) claims 1,6	1-19
:		
	·	

International application No. PCT/IB2005/000132

INTERNATIONAL SEARCH REPORT

Box II	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This Inter	national Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
	Although claim 19 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
t	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
. П.	Claims Nos.:
	because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III(Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This Interr	national Searching Authority found multiple inventions in this international application, as follows:
	see additional sheet
	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
	1
4. N	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is estricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark o	The additional search fees were accompanied by the applicant's protest. X No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-5,8-15,17

amorphous rosuvastatin magnesium salt and the process for its preparation

2. claims: 6,7

process for the preparation of crystalline rosuva statin magnesium salt $% \left(1\right) =\left(1\right) \left(1\right) +\left(1\right) \left(1\right) \left(1\right) +\left(1\right) \left(1\right)$

3. claim: 16

process for the preparation of rosuva statin calcium salt $% \left(1\right) =\left(1\right) \left(1\right) \left($

4. claim: 18 and 19

pharmaceutical composition comprising rosuvastatin magnesium salt and its use as HMG-CoA reductase inhibitor in the treatment of hyperlipidemia

 $1 + \underbrace{\quad \text{nation on patent family members}}$

	Patent document ed in search report		Publication date		Patent family member(s)		Publication date
	0 0160804	A	23-08-2001	AU .	775569	B2	05-08-2004
W	, 0100004	, ,	20 00 2001	AU	3208401		27-08-2001
				BG	106969		30-04-2003
				BR	0108378		11-03-2003
				CA	2397450		23-08-2001
				CN	1418198		14-05-2003
				CZ.	20022754		13-11-2002
				EË ~	200200445	Α	15-12-2003
				EΡ	1263739	A1	11-12-2002
				MO	0160804	A1	23-08-2001
				HU	0204051	A2	28-05-2003
				JP	2003523334	T	05-08-2003
				NO	20023853		14-08-2002
				NZ	520032		26-03-2004
				PL	356472		28-06-2004
				SK	11742002		04-02-2003
ĺ				US	2003045718		06-03-2003
			•	ZA	200205331	Α	03-10-2003
							15 11 0004
Į US	6589959	B1	08-07-2003	AT	282027		15-11-2004
				AU	762909		10-07-2003
				AU	1882600		01-08-2000
				BR	9916786 2356212		16-10-2001 20-07-2000
				CA CN	1333756		30-01-2002
				CZ	20012460		17-10-2001
				DE	69921855		16-12-2004
				EE	200100359		16-12-2002
				EP	1144389		17-10-2001
				ËS	2232194		16-05-2005
				WO	0042024		20-07-2000
			•	HK	1040989		06-05-2005
				HU	0104828		29-07-2002
				ID	29432		30-08-2001
				JP	2002539078	Τ .	19-11-2002
				NO	20013368		05-09-2001
				NZ	512560		29-08-2003
				PL	348775		17-06-2002
				RU	2236404		20-09-2004
				SK	9632001		03-12-2001
				TR	200101894		21-12-2001
				US	2004009997		15-01-2004
				ZA 	200105187	H 	23-09-2002
	0521471	Α	07-01-1993	AT	197149		15-11-2000
Lí	00217/1	П	J, UI 133J	CA	2072945		02-01-1993
				CY	2226		18-04-2003
				DE	69231530		30-11-2000
				DE	69231530		13-06-2001
				DK	521471		05-02-2001
				EP	0521471		07-01-1993
,				ES.	2153824		16-03-2001
				GR	3035189		30-04-2001
				HK	1011986		13-07-2001
				HÜ	220624		28-03-2002
				HÜ	61531		28-01-1993
				JP	2648897		03-09-1997
				JP	5178841		20-07-1993
1							

I ____ nation on patent family members

remational Application No

				f		
Patent document cited in search report		Publication date		Patent family member(s)	•	Publication date
EP 0521471	Α		KR	9605951	B1	06-05-1996
			LU	91042	A9	24-11-2003
			NL	300125	I 1	01-07-2003
			PΤ	521471		30-04-2001
			US	RE37314		07-08-2001
			US	5260440	Α	09-11-1993
WO 03016317	A1	27-02-2003	US	2002099224	A1	25-07-2002
			CA	2450820	A1	27-02-2003
			CN	1543468		03-11-2004
			CZ	20040337		12-01-2005
			EP	1425287		09-06-2004
			HR	20040255		31-08-2004
			JP	2005500382		06-01-2005
			NZ	529913		24-03-2005
			SK	1402004		03-01-2005
			TR	200302281		21-09-2004
			US	2003114685		19-06-2003
			US	2004176615		09-09-2004
			ZA 	200309373	A 	02-12-2004
WO 2004014872	A1	19-02-2004	AU	2003251369		25-02-2004
			CA	2495296		19-02-2004
			EP	1539711	A1	15-06-2005
WO 2004108691	A1	16-12-2004	NONE			
WO 2005021511	A1	10-03-2005	AU	2003269478	A1	i6-03-2005